BCL6 promotes the methotrexate-resistance by upregulating ZEB1 expression in children with acute B lymphocytic leukemia.
To investigate the effect of BCL6 on methotrexate-resistant children with acute B lymphoblastic leukemia (B-ALL) and its underlying mechanism. Bone marrow samples of B-ALL children diagnosed at The Children & Women's Healthcare of Laiwu City from June 2014 to February 2017 were collected. Subjects were assigned into methotrexate-resistant group (n=8) and non-resistant group (n=32) according to the follow-up outcome. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) was performed to detect expressions of BCL6 and E-cadherin in bone marrow tissues. Cell cycle and apoptosis of methotrexate-resistant B-ALL cells (BALL-1/MTXR cells) were detected after overexpression or inhibition of BCL6, respectively. Western blot was performed to determine the protein levels of E-cadherin and BCL6. The direct binding of BCL6 in the ZEB1 promoter region was verified by the ChIP (chromatin immunoprecipitation) assay. QRT-PCR showed a higher BCL6 expression in bone marrow samples of methotrexate-resistant group than that of the non-resistant group. Moreover, BCL6 was upregulated in BALL-1/MTXR cells than that of untreated B-ALL cells. After knockdown of BCL6 expression, we observed a decreased IC50, increased apoptosis, and arrested the cell cycle in BALL-1/MTXR cells. In addition, increased expression of E-cadherin was found in BALL-1/MTXR cells, which could be reversed by ZEB1 overexpression. ChIP assay suggested that BCL6 bound to the promoter region of ZEB1, so as to promote ZEB1 expression. BCL6 is overexpressed in the bone marrow of methotrexate-resistant children with B-ALL, which is capable of attenuating the sensitivity of B-ALL to methotrexate via promoting ZEB1 expression.